Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Cancer Drugs Fund Debuts To Muted Applause From Pharma, Charities

Executive Summary

The re-launch of the controversial Cancer Drugs Fund in the UK has offered another point for debate about cancer drug pricing, budgetary pressures and the cost of innovation.

Advertisement

Related Content

BMS’ Sprycel Is Latest CDF Drug To Get NICE Clearance For Routine NHS Use
Eisai Predicts "Mayhem" For Kisplyx After NICE Finally Okays Halaven
10 Questions For Bayer's UK CEO On Market Access Reforms In England
UK Cancer Drugs Fund Reforms Get Cautious Welcome, But More Needed

Topics

Advertisement
UsernamePublicRestriction

Register

PS118871

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel